Similar articles

• Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy.

  Sensi M, Anichini A. Sensi M, et al. Clin Cancer Res. 2006 Sep 1;12(17):5023-32. doi: 10.1158/1078-0432.CCR-05-2682. Clin Cancer Res. 2006. PMID: 16951217 Review.
• [New immunotherapy for patients with neoplasms using tumor antigens recognized by T lymphocytes].

  Kawakami Y. Kawakami Y. Nihon Naika Gakkai Zasshi. 1998 Dec 10;87(12):2536-44. Nihon Naika Gakkai Zasshi. 1998. PMID: 9922678 Review. Japanese. No abstract available.
• [HLA-restricted cancer-specific killer T cells].

  Harada M, Itoh K. Harada M, et al. Nihon Rinsho. 2005 Apr;63 Suppl 4:579-84. Nihon Rinsho. 2005. PMID: 15861714 Review. Japanese. No abstract available.
• T-cell epitope peptide vaccines.

  Elsawa SF, Rodeberg DA, Celis E. Elsawa SF, et al. Expert Rev Vaccines. 2004 Oct;3(5):563-75. doi: 10.1586/14760584.3.5.563. Expert Rev Vaccines. 2004. PMID: 15485336 Review.
• Tumour escape from the immune response: the last hurdle for successful immunotherapy of cancer?

  Pawelec G. Pawelec G. Cancer Immunol Immunother. 1999 Oct;48(7):343-5. doi: 10.1007/s002620050584. Cancer Immunol Immunother. 1999. PMID: 10501845 Free PMC article. No abstract available.